Zobrazeno 1 - 9
of 9
pro vyhledávání: '"de Wit GF"'
Autor:
Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Geurts BS; Netherlands Cancer Institute, Netherlands., Battaglia TW; Netherlands Cancer Institute, Amsterdam, Netherlands., van Berge Henegouwen JM; Erasmus MC, Rotterdam, Netherlands., de Wit GF; Netherlands Cancer Institute, Amsterdam, Netherlands., Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Wijngaart H; Maastricht University Medical Centre, Netherlands., van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, Netherlands., de Leng WWJ; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Jansen AML; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Chalabi M; Netherlands Cancer Institute, Amsterdam, Netherlands., van Herpen CML; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands., Devriese LA; University Medical Center Utrecht Cancer Center, Utrecht, Netherlands., Erdkamp FLG; Zuyderland Medisch Centrum, Netherlands., Labots M; Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, Netherlands., de Jonge MJA; Erasmus MC Cancer Institute, Rotterdam, Netherlands., Kerver ED; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands., Bins AD; Amsterdam UMC, Amsterdam, Netherlands., Leek LVM; Netherlands Cancer Institute, Amsterdam, Netherlands., Notohardjo JCL; Amsterdam UMC Location VUmc, Amsterdam, Netherlands., van den Eertwegh AJM; Amsterdam UMC, Netherlands., Wessels LFA; The Netherlands Cancer Institute, Amsterdam, NH, Netherlands., Verheul HMW; Erasmus MC, Rotterdam, Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., van de Haar J; The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 18. Date of Electronic Publication: 2024 Jul 18.
Autor:
Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Leiden, The Netherlands., van der Wijngaart H; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Spiekman IA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Beek DM; Hartwig Medical Foundation, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Jansen AM; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WW; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
Publikováno v:
The Journal of pathology [J Pathol] 2024 Jul; Vol. 263 (3), pp. 288-299. Date of Electronic Publication: 2024 May 15.
Autor:
Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands., Geurts BS; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Wit GF; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Kusters B; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Beerepoot LV; Department of Internal Medicine, ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis), Tilburg, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Development Biology, Maastricht University Center+, Maastricht, The Netherlands., Buter J; Department of Medical Oncology, Amsterdam University Medical Center, Location VuMC, Amsterdam, The Netherlands., Gelderblom HAJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Voest EE; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam,The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.
Publikováno v:
The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. 431-440.
Autor:
Battaglia TW; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Mimpen IL; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Traets JJH; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., van Hoeck A; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Noë M; Department of Pathology, Antoni van Leeuwenhoek/the Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Vos JL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cornelissen S; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Alkemade M; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Zuur CL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands., Cuppen E; Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht 3584CX, the Netherlands; Hartwig Medical Foundation, Science Park, Amsterdam 1098XH, the Netherlands., Wessels L; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Faculty of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands., van de Haar J; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Voest E; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. Electronic address: e.voest@nki.nl.
Publikováno v:
Cell [Cell] 2024 Apr 25; Vol. 187 (9), pp. 2324-2335.e19. Date of Electronic Publication: 2024 Apr 09.
Autor:
Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Looze EJ; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van Berge Henegouwen JM; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Simes RJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sjoquist KM; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van der Wijngaart H; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Sebastian L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Espinoza D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Lin FP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Publikováno v:
International journal of cancer [Int J Cancer] 2023 Oct 01; Vol. 153 (7), pp. 1413-1422. Date of Electronic Publication: 2023 Jul 10.
Autor:
Schutte T; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Medical Oncology, de Boelelaan, Amsterdam, The Netherlands., Zeverijn LJ; The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, CX Amsterdam, The Netherlands., Geurts BS; The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, CX Amsterdam, The Netherlands., de Wit GF; The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, CX Amsterdam, The Netherlands., Kok M; The Netherlands Cancer Institute, Department of Medical Oncology, CX Amsterdam, The Netherlands., Opdam FL; The Netherlands Cancer Institute, Department of Medical Oncology, CX Amsterdam, The Netherlands.
Publikováno v:
The oncologist [Oncologist] 2023 Jul 05; Vol. 28 (7), pp. e493-e497.
Autor:
Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Berge Henegouwen JM; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wijngaart H; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands., Opdam FL; Department of Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Cirkel GA; Department of Medical Oncology, Meander, Amersfoort, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands., Hoeben A; Department of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., Kerver ED; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands., Bins AD; Department of Medical Oncology, Amsterdam University Medical Centre, location AUMC, Amsterdam, the Netherlands., Erdkamp FGL; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geelen, the Netherlands., van Rooijen JM; Department of Medical Oncology, Martini Hospital, Groningen, the Netherlands., Houtsma D; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, the Netherlands., de Groot JB; Department of Medical Oncology, Isala, Zwolle, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.; Oncode Institute, Utrecht, the Netherlands. e.voest@nki.nl.
Publikováno v:
BMC cancer [BMC Cancer] 2023 Mar 04; Vol. 23 (1), pp. 205. Date of Electronic Publication: 2023 Mar 04.
Autor:
de Vries NL; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., Veninga V; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Chalabi M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ijsselsteijn ME; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van der Ploeg M; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van den Bulk J; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Ruano D; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JB; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Zeverijn LJ; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Geurts BS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Wit GF; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Battaglia TW; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands., Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Wessels LFA; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of EEMCS, Delft University of Technology, Delft, The Netherlands., Koning F; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., de Miranda NFCC; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. n.f.de_miranda@lumc.nl., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl.; Oncode Institute, Utrecht, The Netherlands. e.voest@nki.nl.
Publikováno v:
Nature [Nature] 2023 Jan; Vol. 613 (7945), pp. 743-750. Date of Electronic Publication: 2023 Jan 11.
Autor:
Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., van Waalwijk van Doorn-Khosrovani SB; CZ Health Insurance, Tilburg, Netherlands., van Roy AAMGP; CZ Health Insurance, Tilburg, Netherlands., Timmers L; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., Ly Tran TH; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., de Boer JE; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., de Wit GF; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Blijlevens N; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands., Wymenga ANM; Department of Medical Oncology, Medical Spectrum Twente, Enschede, Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2022 Feb; Vol. 23 (2), pp. 198-201.